Each bottle contains:
Tiludronic acid (as disodium salt) 50 mg
Tiludronic acid, a bisphosphonate, inhibits bone resorption in horses. Tildren regulates bone tissue remodelling in those cases where too much bone resorption (i.e. elevated activity of osteoclasts) occurs. It has an anti-inflammatory effect on arthritis, by inhibiting the secretion of cartilage resorbing enzymes.
Aid in the treatment of lameness associated with osteolytic processes, in spavin and podotrochleosis existing less than 6 months.
Dosage and administration
Use Tildren only after a good diagnosis using full orthopaedic examination with local anaesthesia and a suitable diagnostic imaging technique.
0,1 mg Tiludronic acid / kg bodyweight (1ml solution / 50 k g) per day during 10 days.
Administer slowly I.V. inject alternating left and right during the consecutive days.
Inject the solvent into the bottle containing the powder and carefully mix these 2 components.
Slight muscle tremors and sweating, colic and a local reaction at the site of injection may occur. These reactions usually occur within a few hours after injection, are transient and need no further treatment. Excitation, hypertonia of tail, excess of saliva and tiredness are possible adverse reactions. Make sure that the horse can lie down without restrictions.
Avoid contact with eyes and skin. Wear gloves while preparing the solution. Wash hands afterwards. Avoid self-injection.
Do not use in horses under 3 years of age. Do not use in horses with impaired kidney function.
The Netherlands: 0 days
Do not mix the reconstituted solution with two-valent ions, such as Ca2+ and Mg2+.
The use during gestation and lactation has been examined insufficiently. Use in carrying or lactating mares is not recommended.
It is recommended to lower the speed of injection in hypocalcaemic horses or horses with functional heart disorders.
Store at 15 – 25°C.
Keep out of reach and sight of children.
10 bottles of 50 g powder each.
10 bottles of 10ml solvent each.
REG NL 10079 UDD